Diabetica Ltd.
This article was originally published in Start Up
Executive Summary
In contrast to a host of companies pursuing GLP-1 pathway in diabetes, Diabetica is pioneering GIP research. Because there is currently no marketed antagonist to make insulin work better in the body, as Diabetica believes its GIP agonist will, the company hopes that, at the end of the day, it won't be competing with other compounds at all.
You may also be interested in...
Best of Blog: Start-Up March 2008
"Best of the Blog" is a monthly column highlighting the best of our free online content at www.windhover.com/blog. This month: A DPP-IV HeadScratcher (obesity & type 2 diabetes) tdiabetes drugs); Cardionet & The Bear (Implantable remote monitoring device); and When Life Gives you Lemons, Make Lemonade (pain drugs).
The Double-edged Sword of Diabetes Drug Development
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.